Dissociation of responsiveness to thyrotropin-releasing hormone and thyroid suppressibility following antithyroid drug therapy of hyperthyroidism
- PMID: 821960
- DOI: 10.1210/jcem-43-3-543
Dissociation of responsiveness to thyrotropin-releasing hormone and thyroid suppressibility following antithyroid drug therapy of hyperthyroidism
Abstract
Responsiveness to synthetic thyrotropin-releasing hormone (TRH), thyroid suppressibility by triiodothyronine (T3) and the outcome of hyperthyroidism following prolonged therapy with thionamides were studied in a group of 35 patients with toxic diffuse goiter. TRH and T3 suppression tests were performed 10 days to 24 months (mean 4 months) after withdrawal of antithyroid drugs. Nineteen patients were euthyroid and had a normal thyrotropin (TSH) response to TRH, while 4 were recovering from mild hypothyroidism due to overtreatment and had an exaggerated response. No response was observed in 12 patients with recurrent hyperthyroidism. Positive T3 suppression tests were found only in 10 of the 30 cases examined. Peak and net 2 h secretion responses of TSH to TRH exhibited a significant inverse correlation with the levels of serum thyroxine and serum triiodothyronine, but were unrelated to the degree of thyroid suppressibility. Relapse or recurrence of thyrotoxicosis occurred in at least 9 of the 23 patients having no evidence of hyperthyroidism at the time of TRH test. Each of them was found to be responsive to TRH, while the T3 suppression test was negative in 8 and had to be discontinued in one because of thyrotoxic symptoms. The present data indicate that during the early period after completion of a prolonged course of antithyroid drug therapy responsiveness to TRH in toxic diffuse goiter is: a) correlated with circulating thyroid hormones, b) unrelated to the degree of thyroid suppressibility by T3 and c) of little value in predicting the long-term results of treatment.
Similar articles
-
The TRH test in the course of treatment of hyperthyroidism.Clin Endocrinol (Oxf). 1975 Mar;4(2):165-72. doi: 10.1111/j.1365-2265.1975.tb01523.x. Clin Endocrinol (Oxf). 1975. PMID: 805680
-
Pituitary unresponsiveness to thyrotropin-releasing hormone in thyrotoxic patients during chronic anti-thyroid drug therapy and in rats previously treated with excess thyroid hormone.J Clin Endocrinol Metab. 1975 Jun;40(6):942-8. doi: 10.1210/jcem-40-6-942. J Clin Endocrinol Metab. 1975. PMID: 805794
-
Pituitary-thyroid regulation in euthyroid patients with Graves' disease previously treated with antithyroid drugs.J Clin Endocrinol Metab. 1976 Aug;43(2):419-27. doi: 10.1210/jcem-43-2-419. J Clin Endocrinol Metab. 1976. PMID: 59733
-
[Thyrostatic treatment and its adverse effects].Vnitr Lek. 2013 Nov;59(11):989-95. Vnitr Lek. 2013. PMID: 24279443 Review. Czech.
-
Ehe diagnosis and treatment of thyrotoxicosis.Clin Endocrinol (Oxf). 1976 Nov;5(6):687-707. doi: 10.1111/j.1365-2265.1976.tb03872.x. Clin Endocrinol (Oxf). 1976. PMID: 827398 Review. No abstract available.
Cited by
-
Spontaneous hypothyroidism after antithyroid treatment of hyperthyroid Graves' disease.J Endocrinol Invest. 1981 Oct-Dec;4(4):399-402. doi: 10.1007/BF03348302. J Endocrinol Invest. 1981. PMID: 6801105
-
Clinical application of a cytochemical bioassay for the determination of thyroid stimulating hormone.J Endocrinol Invest. 1979 Oct-Dec;2(4):395-400. doi: 10.1007/BF03349339. J Endocrinol Invest. 1979. PMID: 119800
-
Response to TRH, serum thyroid hormone concentration, and serum markers of autoimmunity after antithyroid therapy in Graves' disease.J Endocrinol Invest. 1978 Jan;1(1):9-16. doi: 10.1007/BF03346765. J Endocrinol Invest. 1978. PMID: 90688 No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources